Clinical signs in GRMD dogs.

The main clinical signs observed in GRMD dogs during treatment with bortezomib (three, four and five months of age). There were different phenotypes, but the main clinical signs related to muscular dystrophy progression were common to all of the dogs in the study. For physiological studies of GRMD, please see the reference [63] showing an in situ protocol to measure the force generated by a single muscle in dogs.